(Q33618126)
Statements
1 reference
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors (English)
1 reference
B I Sikic
1 reference
H A Wakelee
1 reference
A Patnaik
1 reference
M Mita
1 reference
N L Fox
1 reference
R Miceli
1 reference
S J Ullrich
1 reference
G A Fisher
1 reference
A W Tolcher
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference